查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138280

Prader-Willi 綜合徵全球市場-2022-2029

Global Prader-Willi Syndrome Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

關鍵驅動因素：監管機構指定的靈丹妙藥、被診斷的患者人數增加、人類生長激素療法的使用增加、強大的管道、擴大的戰略聯盟以及在 PWS 診斷和治療方面的領先優勢 技術的使用和意識的提高.

對 Prader-Willi 綜合徵治療的持續研究正在推動市場的增長。

正在進行的治療 Prader-Willi 綜合徵的研究正在推動全球市場的增長。例如，根據 ClinicalTrials.gov，目前有三項活躍的研究。根據政府的說法，目前有三項正在進行的研究。即，由 Harmony Biosciences, LLC 贊助的一項隨機、雙盲、安慰劑對照的第 2 期研究，以評估 Pitrisant 在 Prader-Willi 綜合徵患者中的安全性和有效性，隨後是一項開放標籤擴展研究；第 3 階段，多中心、開放標籤研究，預計於 2022 年 10 月完成。一項多中心、開放標籤、多隊列研究（由輝瑞公司贊助，計劃於 2024 年 5 月 25 日結束）評估生長激素對 Prader-Willi 綜合徵患者和 Prader-Willi 綜合徵患者開放標籤的長期療效和安全性二氮秦/膽鹼緩釋片在糖尿病患者中的安全性評價（由 Soleno Therapeutics, Inc. 贊助，將於 2023 年 6 月完成）。這是一項針對 Prader-Willi 綜合徵患者的開放標籤長期安全性評估研究（計劃於 2023 年 6 月結束）。此外，目前正在招募另外 12 項關於 Prader-Willi 綜合徵各種干預措施的研究，推動全球市場的增長。

缺乏認識和治療效果低下正在減緩 Prader-Willi 綜合徵 (PWS) 市場的增長。

然而，目前治療的療效有限、對 Prader-Willi 綜合徵的低認識以及與該疾病相關的並發症的存在預計將抑制市場增長。

Prader-Willi 綜合徵 (PWS) 市場 - 行業分析

Prader-Willi 綜合徵 (PWS) 市場報告根據波特五力、研發、流行病學、監管、價格和管道分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

COVID-19 是一種非典型健康問題，對全球普拉德-威利綜合徵 (PWS) 市場的增長產生了深遠的影響。在其爆發過程中，各種監管機構實施了限制措施，以遏制感染在人際關係中的傳播。因此，許多普拉德-威利綜合徵 (PWS) 病例仍未被發現，因此很難按時進行定期檢查。此外，運輸限制影響進出口，影響許多市場參與者的供應鏈，並共同降低市場上普拉德-威利綜合徵 (PWS) 的可用性，減少銷售，對市場增長產生負面影響。

Prader-Willi 綜合徵 (PWS) 市場報告將提供對大約 40 多個市場數據表、45 多個數字和 200 多頁（大約）的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 調查與研發
      • 市場策略
    • 約束因素
      • 認知度低
      • 治療效果低
      • 嚴格的監管機構
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學分析
  • 研發
  • 管道分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 重組生長激素
  • 維羅拉尼
  • 鹽酸倍他司汀
  • 二氮秦膽鹼 CR
  • FE-992097
  • 其他

第 8 章按銷售渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 9 章給藥途徑

  • 口語
  • 注入

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Pfizer
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Novartis
  • Soleno Therapeutics
  • Saniona
  • Millendo Therapeutics, Inc.
  • Levo Therapeutics, Inc.
  • Rhythm Pharmaceuticals
  • Essentialis, Inc.
  • LG Corp
  • Novo Nordisk

第13章 DataM

簡介目錄
Product Code: DMPH2128

Market Overview

Prader-Willi syndrome market is expected to grow at a CAGR of 4.5% in the forecast period (2022-2029).

Prader-Willi syndrome (PWS) is a genetic disorder due to the deletion of a part of the father's chromosome 15. Prader-Willi syndrome can also be due to the presence of two copies of chromosome 15 inherited by the mother only, leading to their suppression during gene formation. PWS therapeutics have a wide scope in the global market, as no known cure is available for such a complex genetic disorder.

Market Dynamics

The major driving forces are increasing the number of special drug designations from regulatory bodies, an increasing number of the diagnosed patient population, growing human growth hormone therapy coverage rate, a strong pipeline, growing strategic alliances, use of advanced technologies for the diagnosis and treatment of PWS, and surging awareness.

The ongoing research on treating Prader-Willi syndrome is pushing the market's growth.

The ongoing studies for treating Prader-Willi syndrome are fueling the global market growth. For instance, according to Clinical Trials.gov currently, 3 studies are active; namely, a study sponsored by Harmony Biosciences, LLC titled a randomized, double-blind, placebo-controlled phase 2 study to evaluate the safety and the efficacy of Pitolisant in patients with Prader-Willi syndrome, followed by an open-label extension, which is estimated to complete by October 2022, a phase 3 multicenter, open-label, multi-cohort study for evaluation of the efficacy and safety of somatropin in Japanese participants with Prader-Willi syndrome (PWS) study sponsored by Pfizer, with the estimated completion on May 25, 2024, and an open-label, long-term safety evaluation of diazoxide choline controlled-release tablet in patients with Prader-Willi syndrome sponsored by Soleno Therapeutics, Inc. with estimated completion on June 2023. Furthermore, 12 more studies on different interventions for Prader-Willi syndrome are currently recruiting, driving the global market growth.

The lack of awareness and limited treatment efficiency slows the Prader-Willi syndrome (PWS) market growth.

However, the limited efficacy of the current therapies, lack of awareness of the Prader-Willi syndrome, and the presence of complications associated with the diseases are expected to restrain the market growth.

Prader-Willi syndrome (PWS) Market-Industry analysis.

The Prader-Willi syndrome (PWS) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis, Etc.

COVID-19 Impact Analysis

COVID-19 is an atypical health concern that has profoundly impacted the global Prader-Willi syndrome (PWS) market growth. In the course of the outbreak, restrictions were imposed by different regulatory bodies for controlling the spread of the infection regarding the socializing of people, which made it difficult to get regular healthcare check-ups on time leaving many cases of Prader-Willi syndrome (PWS) undetected. Moreover, the restrictions on transportation affected the import and export, affecting the supply chain of many market players, overall reducing the availability of Prader-Willi syndrome (PWS) in the market, reducing sales, and negatively impacting the market growth globally.

Segment Analysis

The recombinant growth hormone treatment for Prader-Willi syndrome (PWS) is estimated to oppress the market during the forecast period (2022-2029).

The recombinant growth hormones segment is expected to grow rapidly over the forecast period (2022-2029). Currently, the pharmacological management of Prader-Willi syndrome (PWS) focuses mainly on using human growth hormone (HGH) supplementation, which is approved in the US. Growth hormone(GH) supplementation constitutes the primary component of the entire therapeutic market composition due to the nearly ubiquitous deficiency of growth hormone (GH) in PWS patients. Some majorly approved GH therapies include Pfizer's Genotropin (somatropin), other major brands such as Norditropin (Novo Nordisk), and others in the US. Another approved drug is Omnitrope (somatropin [rDNA origin] injection) from Sandoz. Also, ongoing clinical trials on growth hormones are expected to boost the market growth. For instance, a study sponsored by OPKO Health, Inc. on safety and dose-finding study of different MOD-4023 dose levels compared to daily R-human Growth Hormone (hGH) therapy in pre-pubertal growth hormone deficient children is estimated to complete on December 12, 2024, another phase 3, open-label, randomized, multicenter, 12 months, study on the efficacy and the safety of weekly MOD-4023 compared to daily Genotropin - therapy in pre-pubertal children with growth hormone deficiency sponsored by OPKO Health, Inc. and estimated completion is in December 2022.

Geographical Analysis

North America is predicted to hold most of the market share.

North America oppressed the global Prader-Willi syndrome market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing prevalence of Prader-Willi syndrome in the region and a growing number of ongoing research and development activities on the Prader-Willi syndrome. For instance, according to the National Institute of Health, the number of individuals with Prader Willi Syndrome is approximately 400000, and 20000 of these cases are in the United States. The presence of organizations creating awareness about PWS in the region is also expected to drive market growth. For instance, the Prader-Willi Syndrome Association (USA) has provided life-saving research, crisis, family support, medical and new parent support since 1975 and The Foundation for Prader-Willi Research, a non-profit corporation established in 2003. Furthermore, the presence of highly advanced and robust healthcare infrastructures in North America contributes to its dominance over the global Prader-Willi syndrome market.

Competitive Landscape

The key players operating in the global Prader-Willi syndrome market are Novartis, Soleno Therapeutics, Saniona, Pfizer, Millendo Therapeutics, Inc., Levo Therapeutics, Inc., Rhythm Pharmaceuticals, Essentialis, Inc., LG Corp and Novo Nordisk. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Prader-Willi syndrome market globally. For instance, on Aug 25, 2022, Novartis announced to spin off the Sandoz business creating a standalone company. Also, on July 20, 2022, FDA acknowledged that data from a randomized withdrawal period of Study C602 by Soleno Therapeutics have the potential to support an NDA submission.

Pfizer Inc.

Overview

Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.

Product Portfolio

Pfizer`s Prader-Willi syndrome (PWS) product portfolio has Genotropin and NGENLA.

The Prader-Willi syndrome (PWS) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Research and Development
      • 4.1.1.2. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of Awareness
      • 4.1.2.2. Low Efficacy of Treatment
      • 4.1.2.3. Stringent Regulatory Bodies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiological Analysis
  • 5.3. Research and Developments
  • 5.4. Pipeline Analysis
  • 5.5. Supply Chain Analysis
  • 5.6. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Recombinant Growth Hormone
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Beloranib
  • 7.4. Betahistine Hydrochloride
  • 7.5. Diazoxide Choline CR
  • 7.6. FE-992097
  • 7.7. Others

8. By Distribution Channels

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channels Segment.
    • 8.1.2. Market Attractiveness Index, By Distribution Channels Segment
  • 8.2. Hospital Pharmacy
    • 8.3.1. Introduction
    • 8.3.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.4. Retail Pharmacy
  • 8.5. Online Pharmacy

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Injectable

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Pfizer
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis
  • 12.3. Soleno Therapeutics
  • 12.4. Saniona
  • 12.5. Millendo Therapeutics, Inc.
  • 12.6. Levo Therapeutics, Inc.
  • 12.7. Rhythm Pharmaceuticals
  • 12.8. Essentialis, Inc.
  • 12.9. LG Corp
  • 12.10. Novo Nordisk

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact